| Date | Title | | | 05/16/12 | AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC|
- Tivozanib is the First Agent to Demonstrate Greater than One Year
PFS in Patients without Prior Systemic Treatment -
- First Pivotal Trial vs. Active Targeted Agent in First-Line
Advanced RCC -
- Study Results Demonstrate Unique Combination of Superior PFS and
Favorable Tolerability -
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--May. 16, 2012--
AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today
... |
|  | | 05/03/12 | AVEO Reports First Quarter 2012 Financial Results and Recent Developments| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 3, 2012--
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated
financial results for the first quarter of 2012 and reviewed key first
quarter accomplishments.
“Since the achievement of the primary endpoint in our TIVO-1 study early
in the first quarter, we’ve seen an increase in excitement in the
medical oncology community for tivozanib and are looking forward to
reporting the de... |
| | | 05/02/12 | AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung Cancer|
Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and
Demonstrated Clinical Activity; Study Results Did Not Reach Statistical
Significance
Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 2, 2012--
AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary
data from the exploratory, randomized Phase 2 study comparing the
combination of ficlatuzumab and g... |
| |
|
